NZ204438A - Controlled release pharmaceutical compositions - Google Patents

Controlled release pharmaceutical compositions

Info

Publication number
NZ204438A
NZ204438A NZ204438A NZ20443883A NZ204438A NZ 204438 A NZ204438 A NZ 204438A NZ 204438 A NZ204438 A NZ 204438A NZ 20443883 A NZ20443883 A NZ 20443883A NZ 204438 A NZ204438 A NZ 204438A
Authority
NZ
New Zealand
Prior art keywords
tablet
salt
base
weight
pharmacologically active
Prior art date
Application number
NZ204438A
Other languages
English (en)
Inventor
B Oshlack
S T Leslie
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NZ204438A publication Critical patent/NZ204438A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ204438A 1982-06-21 1983-06-01 Controlled release pharmaceutical compositions NZ204438A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/390,540 US4443428A (en) 1982-06-21 1982-06-21 Extended action controlled release compositions

Publications (1)

Publication Number Publication Date
NZ204438A true NZ204438A (en) 1985-05-31

Family

ID=23542881

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ204438A NZ204438A (en) 1982-06-21 1983-06-01 Controlled release pharmaceutical compositions

Country Status (16)

Country Link
US (1) US4443428A (enExample)
EP (1) EP0097523B1 (enExample)
JP (1) JPS5925316A (enExample)
AR (1) AR230783A1 (enExample)
AT (1) ATE31874T1 (enExample)
AU (1) AU556588B2 (enExample)
CA (1) CA1205381A (enExample)
DE (1) DE3375283D1 (enExample)
ES (1) ES8500739A1 (enExample)
IE (1) IE55190B1 (enExample)
IL (1) IL68887A (enExample)
MX (1) MX156495A (enExample)
NZ (1) NZ204438A (enExample)
PT (1) PT76873B (enExample)
SE (1) SE8303531D0 (enExample)
ZA (1) ZA834424B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729927B2 (ja) * 1983-04-09 1995-04-05 日研化学株式会社 テオフィリン徐放性製剤
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
AU611461B2 (en) * 1987-07-29 1991-06-13 Pharmacia & Upjohn Company Controlled release of antibiotic salts from an implant
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
JPH04504103A (ja) * 1988-07-01 1992-07-23 ファルマシア・アンド・アップジョン・カンパニー 植込錠から制御放出される抗生物質塩
JP2538134B2 (ja) * 1991-04-08 1996-09-25 田辺製薬株式会社 徐放性製剤およびその製造法
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
AU6552699A (en) * 1993-05-10 2000-03-02 Euro-Celtique S.A. Controlled release formulation
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
HU218673B (hu) * 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
AUPM814994A0 (en) * 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US7943173B2 (en) * 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
EP1708686B1 (en) * 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
DE602004031771D1 (de) * 2003-12-31 2011-04-21 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP2008506788A (ja) * 2004-05-21 2008-03-06 アルザ・コーポレーシヨン 多剤形態の送達用の薬用量形態
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
TW200621306A (en) * 2004-10-22 2006-07-01 Dynamis Therapeutics Inc Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2006116247A1 (en) * 2005-04-25 2006-11-02 Teva Pharmaceuticals Usa, Inc. Extended release formulations
US20070160641A1 (en) * 2006-01-12 2007-07-12 Eun-Hyun Jang Coated medical devices and methods of making the same
KR101486228B1 (ko) * 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
KR20130105935A (ko) * 2008-07-07 2013-09-26 유로-셀티큐 에스.에이. 요폐의 치료를 위한 아편유사제 길항제의 용도
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420300D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Tablet
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
CN117122573A (zh) * 2023-07-12 2023-11-28 山东新华制药股份有限公司 茶碱缓释片及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE856039C (de) * 1944-04-22 1952-11-17 Boehringer & Soehne Gmbh Verfahren zur Darstellung von haltbaren Praeparaten aus Acylsalicylsaeuren und Nebenalkaloiden der Chinarinde
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
FR5581M (enExample) * 1965-06-09 1967-12-04
ES335314A1 (es) * 1966-01-06 1967-12-01 Ceskoslovenska Akademie Ved Mejoras introducidas en la preparacion de vehiculos insolubles de sustancias al menos parcialmente solubles, biologicamente activas.
GB1182179A (en) * 1966-06-22 1970-02-25 Nippon Kayaku Kk Anti-Peptic Ulcer Composition.
NL6715531A (enExample) * 1966-11-16 1968-05-17
NL148500B (nl) * 1967-10-07 1976-02-16 Scherer Gmbh R P Depotgeneesmiddelen in capsulevorm.
US3525790A (en) * 1968-08-21 1970-08-25 Mortimer D Sackler Dihydroquinidine polygalacturonate and dihydroquinidine galacturonate compositions
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
FR2255890B1 (enExample) * 1973-12-28 1978-01-13 Centre Etd Ind Pharma
US4002756A (en) * 1974-04-22 1977-01-11 Interx Research Corporation Useful pro-drug forms of theophylline
US4049791A (en) * 1974-06-21 1977-09-20 Delco Chemical Company, Inc. Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents
DE2517434A1 (de) * 1975-04-19 1976-10-28 Artesan Gmbh Fabrik Chemisch P Arzneimittel
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
DE2717062C2 (de) * 1977-04-18 1982-11-25 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antitussiver Wirkung
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
AU537741B2 (en) * 1979-03-21 1984-07-12 British Technology Group Limited Controlled release compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5698220A (en) * 1988-08-30 1997-12-16 Pfizer Inc. Asymmetric membranes in delivery devices
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices

Also Published As

Publication number Publication date
AU1570883A (en) 1984-01-05
IE831448L (en) 1983-12-21
AU556588B2 (en) 1986-11-13
IL68887A0 (en) 1983-10-31
ES523427A0 (es) 1984-11-01
EP0097523A2 (en) 1984-01-04
EP0097523B1 (en) 1988-01-13
MX156495A (es) 1988-08-30
PT76873B (fr) 1986-01-27
DE3375283D1 (en) 1988-02-18
ATE31874T1 (de) 1988-01-15
JPS5925316A (ja) 1984-02-09
CA1205381A (en) 1986-06-03
PT76873A (fr) 1983-07-01
SE8303531D0 (sv) 1983-06-20
JPH0521886B2 (enExample) 1993-03-25
EP0097523A3 (en) 1984-12-12
ES8500739A1 (es) 1984-11-01
ZA834424B (en) 1984-03-28
US4443428A (en) 1984-04-17
AR230783A1 (es) 1984-07-31
IL68887A (en) 1987-07-31
IE55190B1 (en) 1990-06-20

Similar Documents

Publication Publication Date Title
CA1205381A (en) Extended action controlled release compositions
US8506998B2 (en) Pharmaceutical formulation
US5980942A (en) Zero-order sustained release matrix tablet formulations of carbamazepine
DK175627B1 (da) Farmaceutisk præparat til oral indgift med reguleret afgivelse og forlænget virkning
EP0142561B1 (en) Long-acting nifedipine preparation
US3965256A (en) Slow release pharmaceutical compositions
US5266331A (en) Controlled release oxycodone compositions
US4421736A (en) Sustained release diethylpropion compositions
EP0218148B1 (en) Slow-release pharmaceutical composition
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
GB2196852A (en) Sustained release composition
US6579536B1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
US3453360A (en) Universally useful stock material for manufacturing plastic dosage units by compression tableting processes
IE76142B1 (en) Solvent-free pharmaceutical formulation to be administered orally having delayed release of active ingredient and process for its preparation
WO2002049608A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
JP6903430B2 (ja) 徐放性製剤
JPH03500288A (ja) 徐放性ニフェジピン製剤
JPS61183225A (ja) ９，１０‐ジヒドロ麦角アルカロイド含有医薬組成物
AU2019254487A1 (en) Sustained release pyridostigmine compositions
KR840000692B1 (ko) 디피리다몰 서방출형 제제의 제조방법
EP0358665A1 (en) Pharmaceutical compositions having spasmolytic activity
PL203547B1 (pl) Kompozycje gliburidu
SA93140139B1 (ar) مركبات الاوكسيكودون oxycodone منتظمة الانطلاق controlled release